One Thing AI Can’t Do

But it can save lives August 30, 2024 [WEBSITE]( | [UNSUBSCRIBE]( There are some things AI can’t do - but saving lives isn’t one of them. Here’s how to play it. One Thing AI Can’t Do CHRIS CAMPBELL Dear Reader, This year, I’ve become a bit of a mead maniac—obsessed with brewing the perfect batch. Making mead is like stepping back in time. It's an ancient art, a ritual that’s been passed down through generations. You start with simple ingredients: honey, water, and yeast. Maybe you get a little creative and add herbs. (The Celts used heather flowers in their mead for its medicinal properties. The Vikings used meadowsweet. The Greeks? Hyssop. The list goes on.) But the magic happens in the wait. Mead is a slow brew. We’re talking months, sometimes even years. You don’t rush it because you can’t. You let nature do its thing, allowing the flavors to evolve, deepen, and mature. This deliberate process is part of what makes mead so special. It’s what gives mead its character, its soul. But let’s be real—few things in life need to take this long. Some things, like saving lives, don’t get better by hiding them in a dark closet and waiting. They demand speed, precision, and urgency. Unlike mead, which SHOULD take time, discovering and developing life-saving drugs is an area where speed matters—a lot. Every day, every week shaved off the drug discovery process can mean the difference between life and death for countless people. For decades, drug discovery has been this slow, grueling process. You had scientists in lab coats hunched over microscopes, trying to figure out which molecules might, just might, be the magic bullet for some disease. It took years, sometimes decades, and billions of dollars. And even then, more than half of those drugs didn’t make it past the first phase of trials. But now, AI is stepping into the ring… [ALERT] The #1 AI Stock To Buy Now! James Altucher just released an urgent video detailing a brand-new AI stock that could grow by 10X or more over the next few years. But you have to hurry. A major piece of news could be released any day, and it could be what sends this stock SOARING, outperforming AI giants like Nvidia. [Click here for exclusive urgent access.]( The AI Drug Rush And it’s not just frolicking in the fringes—it’s beginning to dominate. The mainstream media isn’t reporting on it, but it’s happening. We’re talking about a leap from a 63% success rate in Phase 1 trials to a mind-blowing 80-90% success rate. Our colleague Ray Blanco calls it the “AI Drug Rush.” And this is the kind of rush that only comes around once in a generation. Our main beat here in ALC: It pays to be optimistic. So if you’re an advocate of this approach… [Click here to see what James thinks about the AI Drug Rush]( and how you can play it in the coming weeks and months. Until next time, Chris Campbell For Altucher Confidential Rate this email Like Dislike Thanks for rating this content! Looks like something went wrong. Please try to rate again. You have [(1) item]( on hold at our warehouse: Item #: [51987]( Status: On hold Value: Approx. $300 Claim by date: 09/03 at 11:59 PM To see how to claim yours simply [click here]( our Head of Customer Experience will show you what you need to do. ☰ ⊗ [ARCHIVE]( [ABOUT]( [Contact Us]( © 2024 Paradigm Press, LLC. 1001 Cathedral Street, Baltimore, MD 21201. By submitting your email address, you consent to Paradigm Press, LLC. delivering daily email issues and advertisements. To end your Altucher Confidential e-mail subscription and associated external offers sent from Altucher Confidential, feel free to [click here.]( Please note: the mailbox associated with this email address is not monitored, so do not reply to this message. We welcome comments or suggestions at feedback@altucherconfidential.com. This address is for feedback only. For questions about your account or to speak with customer service, [contact us here]( or call (844)-731-0984. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of a printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Altucher Confidential is committed to protecting and respecting your privacy. We do not rent or share your email address. Please read our [Privacy Statement.]( If you are having trouble receiving your Altucher Confidential subscription, you can ensure its arrival in your mailbox by [whitelisting Altucher Confidential.](